Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inavolisib plus CDK4/6 inhibitor and letrozole in endocrine-sensitive PIK3CA-mutated HR-positive HER2-negative advanced breast cancer
jRCT2011250053Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Inavolisib + CDK4/6 inhibitor + letrozole with Placebo + CDK4/6 inhibitor + letrozole (2 arms). Started Feb 2026; status: recruiting.
02
Drugs
inavolisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2011250053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250053.